NV-RIMINI-STREET,-INC.
30.9.2020 15:02:09 CEST | Business Wire | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of business software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today revealed significant findings from its recent survey of Oracle PeopleSoft licensees, which was conducted to better understand licensees’ software product and release roadmap strategies, current challenges and application support and operating plans. The survey highlights that an overwhelming 97% of respondents believe their current PeopleSoft releases meet all or most of their business needs. Further, many licensees are taking steps to maximize the value and extend the lifespan of their robust and mature current releases, including moving their PeopleSoft software to a cloud hosting platform, utilizing Application Management Services and switching their annual support to third-party support providers like Rimini Street.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200930005176/en/
Oracle licensees who responded to the Rimini Street survey include a mix of CIOs and VPs of IT, IT directors and managers, application managers, application leads and Oracle administrators across a variety of industries including Financial Services, Retail, Manufacturing, Education, Telecommunications, Building and Construction, Government, Transportation and Logistics, Pharmaceutical and Life Sciences, Insurance, and Oil and Gas.
To access a copy of Rimini Street’s report, “Survey Report: Licensees’ Insights into the Future of Their PeopleSoft Roadmaps,” click here .
Licensees Maximizing the Value and Extending the Lifespan of Current Releases
Instead of investing significant time, resources and capital to perform what they view as expensive, low ROI release upgrades or full migrations to Oracle Cloud ERP, many PeopleSoft licensees are taking steps to maximize the value and extend the lifespan of their current, robust and mature releases.
For example, despite PeopleSoft 9.2 being generally available since March 20131 , 64% of respondents are still running at least part of their business on PeopleSoft 9.1 or earlier releases, which are no longer fully supported by Oracle. Currently, less than 50% of respondents have indicated any definitive plans to upgrade their PeopleSoft applications.
Vendor Support is Expensive and Provides Low Value for PeopleSoft 9.1 or Earlier Releases
For PeopleSoft licensees who are continuing to utilize their current PeopleSoft 9.1 or earlier release and have chosen not to upgrade to PeopleSoft 9.2, they are now in Oracle Sustaining Support and no longer get access to new fixes, critical patch updates or tax, legal and regulatory updates. Despite the reduced service breadth, 72% of respondents running PeopleSoft 9.1 or earlier releases are still paying Oracle for expensive and low value Sustaining Support that does not meet their full support needs, resulting in 43% of these same PeopleSoft licensees also paying Oracle additional fees for supplemental critical tax, legal and regulatory updates, and 39% having to allocate their own resources to help fill the service gap by self-supporting their PeopleSoft environments.
PeopleSoft 9.2 Provides Limited Additional Business Value and ROI
Of those licensees who are currently planning to eventually upgrade to PeopleSoft 9.2, nearly 85% indicated they are doing so primarily for support reasons and not to implement or leverage the benefits of any new features or functional enhancements. In fact, according to a poll by the Quest Oracle Community, nearly half of PeopleSoft 9.2 licensees have rolled out zero new features to end users2 .
Of the respondents who are running PeopleSoft 9.2, 53% indicated that they did not leverage strong innovation on a consistent basis from new Oracle PeopleSoft 9.2 updates. However, despite the updates providing a seemingly low ROI and value, 96% indicated it can be very expensive and time-consuming to apply the Oracle PeopleSoft 9.2 updates, taking up to six weeks to test, validate and apply just one update, requiring an average of three-to-five resources during that time to perform the work.
Despite these significant cost and resources needed to complete an Oracle PeopleSoft 9.2 update, the majority of PeopleSoft 9.2 survey respondents appear to stay current with Oracle’s updates primarily to ensure that they retain access to Oracle full support.
PeopleSoft Licensees are Leveraging the Cloud to Extend the Lifespan of Current Releases
The survey also revealed that cloud continues to play an integral role in the future of licensees’ PeopleSoft roadmaps, with 87% of all respondents currently evaluating, actively moving to, or already running some or all their PeopleSoft applications on a cloud platform. Migrating their PeopleSoft system to a cloud environment can eliminate the need for significant capital investments in data center server refreshes, reduce operating costs and provide better user performance. In fact, 29% of respondents indicate that they have already migrated their PeopleSoft system to a cloud hosting provider. Lifting and shifting existing PeopleSoft software to a cloud environment provides the cloud-related benefits noted above, while allowing the respondents to extend the lifespan of their proven, current software releases for many additional years without having to address aging hardware infrastructure challenges.
Challenges with Oracle Support Persist
Finally, the survey underscores that challenges persist with regard to Oracle annual maintenance and support in comparison to the perceived benefit of that support, consistent with findings from a 2019 survey . The number one issue surfaced in the current survey, cited by 56% of all respondents, is the high annual maintenance and support fees charged by Oracle. Additionally, 43% of respondents cited dissatisfaction with the time it takes for Oracle to respond to issues, 43% of respondents noted that they have to escalate priority tickets to get the right expertise, and 16% of respondents were dissatisfied that Oracle annual maintenance and support does not provide support for customizations as a standard feature.
Rimini Street Helps Organizations Take Back Control of PeopleSoft Roadmaps
Rimini Street enables clients to maximize the value and extend the lifespan of current PeopleSoft releases by saving 50% on vendor annual support fees and up to 90% on the total cost of maintenance for PeopleSoft, while supporting their existing PeopleSoft releases for a minimum of an additional 15 years without any forced upgrades or updates. Clients enjoy faster, more comprehensive support including 10-minute response SLAs for critical P1 issues, the industry’s fastest Legislature-to-LiveTM tax, legal and regulatory updates, and support for custom code and integrations, all at no extra cost. With Rimini Street, IT organizations running PeopleSoft are able to leverage immediate budget and time savings to focus on the strategic priorities of their business, without Oracle dictating their roadmap decisions or timing.
“While our PeopleSoft 9.2 software release more than meets our business needs, we were struggling to justify the cost required to support the platform. In comparison to the cost, time and resources required for us to keep up to date on the vendor’s forced updates just to remain in full support, we were not getting sufficient support from the vendor in return,” said Ho Lee, HR and IT Service Team Leader, Kolon Benit. “We moved to Rimini Street Support and now save significantly on our annual maintenance, plus we are guaranteed a minimum of 15 years’ support for our current PeopleSoft software release. This has enabled us to free up significant resource and budget to focus on more strategic initiatives within the business.”
“Our PeopleSoft survey indicates an overall trend that many PeopleSoft licensees are taking steps to maximize the value and extend the useful life of their current PeopleSoft releases, but they need a better support solution that provides more value at a lower cost, and doesn’t require any forced upgrades or updates for years to come,” said Frank Reneke , group vice president and general manager, Oracle Services, Rimini Street. “PeopleSoft licensees who switch to Rimini Street Support can extend the lifespan of their existing release for a minimum of 15 years with no required updates, upgrades or migrations at up to a 90% total maintenance and support cost savings. Tax, legal and regulatory updates and full customization support are included at no additional charge. They can also leverage Rimini Street Application Management Services for PeopleSoft to run their system – creating an efficient, managed ‘turnkey’ solution that integrates operations and support into a single offering, provided by a single, fully-accountable vendor.”
For more information on Rimini Street Support for PeopleSoft click here .
About Rimini Street, Inc.
Rimini Street, Inc. (Nasdaq: RMNI) is a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner. The Company offers premium, ultra-responsive and integrated application management and support services that enable enterprise software licensees to save significant costs, free up resources for innovation and achieve better business outcomes. To date, more than 3,500 Fortune 500, Fortune Global 100, midmarket, public sector and other organizations from a broad range of industries have relied on Rimini Street as their trusted application enterprise software products and services provider. To learn more, please visit http://www.riministreet.com , follow @riministreet on Twitter and find Rimini Street on Facebook and LinkedIn .
Forward-Looking Statements
Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may,” “should,” “would,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “seem,” “seek,” “continue,” “future,” “will,” “expect,” “outlook” or other similar words, phrases or expressions. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, the duration of and economic, operational and financial impacts on Rimini Street’s business of the COVID-19 pandemic, as well as the actions taken by governmental authorities, clients or others in response to the COVID-19 pandemic; catastrophic events that disrupt Rimini Street’s business or that of its current and prospective clients, changes in the business environment in which Rimini Street operates, including inflation and interest rates, and general financial, economic, regulatory and political conditions affecting the industry in which Rimini Street operates; adverse developments in pending litigation or in the government inquiry or any new litigation; Rimini Street’s need and ability to raise additional equity or debt financing on favorable terms and Rimini Street’s ability to generate cash flows from operations to help fund increased investment in Rimini Street’s growth initiatives; the sufficiency of Rimini Street’s cash and cash equivalents to meet its liquidity requirements; the terms and impact of Rimini Street’s outstanding 13.00% Series A Preferred Stock; changes in taxes, laws and regulations; competitive product and pricing activity; difficulties of managing growth profitably; the customer adoption of Rimini Street’s recently introduced products and services, including its Application Management Services (AMS), Rimini Street Advanced Database Security, and services for Salesforce Sales Cloud and Service Cloud products, in addition to other products and services Rimini Street expects to introduce in the near future; the loss of one or more members of Rimini Street’s management team; uncertainty as to the long-term value of Rimini Street’s equity securities; and those risks discussed under the heading “Risk Factors” in Rimini Street’s Quarterly Report on Form 10-Q filed on August 5, 2020 and as updated from time to time by other filings by Rimini Street with the Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.
© 2020 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.
1 Marketwire: Oracle Releases Oracle’s PeopleSoft 9.2, March 18, 2013: https://yhoo.it/2Cj1VwV
View source version on businesswire.com: https://www.businesswire.com/news/home/20200930005176/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
